{"success":true,"data":{"pressRelease":{"id":"130298","rtpr_id":"nPnc49Q6Ra","ticker":"BLRX","exchange":"NASDAQ","all_tickers":["BLRX"],"title":"BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement","author":"PR Newswire","published_at":"2026-08-28T12:00:01.067Z","article_body":"BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement\n\nPR Newswire\n\nTEL AVIV, Israel, Aug. 28, 2026\n\nTEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)\n(TASE: BLRX) (\"BioLineRx\" or the \"Company\"), a clinical-stage\nbiopharmaceutical company pursuing life-changing therapies in oncology and\nrare diseases, today announced that it has entered into a definitive agreement\nfor the purchase of an aggregate of 1,348,921 of the Company's American\nDepositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per\nADS (or per ADS equivalent) through a registered direct offering. In addition,\nthe Company has agreed to issue accompanying warrants to purchase up to an\naggregate of 2,023,382 ADSs, at a purchase price of $2.78 per ADS (or per ADS\nequivalent) via a concurrent private placement. The warrants will have an\nexercise price of $2.78 per ADS and will expire five years from the issuance\ndate. Each ADS represents six hundred (600) ordinary shares, par value NIS\n0.10 per share, of BioLineRx. The closing of the offering is expected to occur\non or about August 31, 2026, subject to the satisfaction of customary closing\nconditions.\n\nChardan is acting as the exclusive placement agent for the offering.\n\nThe aggregate gross proceeds to the Company from the offering are expected to\nbe $3.75 million, before deducting the placement agent fees and other offering\nexpenses payable by the Company. The Company currently intends to use the net\nproceeds from the offering for research and development activities and working\ncapital and general corporate purposes.\n\nThe ADSs (or ADS equivalents) offered in the registered direct offering (but\nexcluding the securities offered in the private placement and the ADSs\nunderlying the warrants) are being offered pursuant to a \"shelf\" registration\nstatement (File No. 333-276323) filed with the Securities and Exchange\nCommission (\"SEC\") on December 29, 2023 and declared effective on January 5,\n2024. The offering of the ADSs (or ADS equivalents) to be issued in the\nregistered direct offering is being made only by means of a prospectus,\nincluding a prospectus supplement, forming a part of the effective\nregistration statement. A final prospectus supplement and the accompanying\nprospectus relating to the registered direct offering will be filed with the\nSEC and be available at the SEC's website at www.sec.gov (http://www.sec.gov)\n. Electronic copies of the final prospectus supplement and the accompanying\nprospectus relating to the securities being offered may also be obtained, when\navailable, by contacting Chardan at One Pennsylvania Plaza, Suite 4800, New\nYork, NY 10119, by telephone at (646) 465-9065 or e-mail at\nvdealwis@chardan.com (mailto:vdealwis@chardan.com) .\n\nThe securities issued in the private placement and the unregistered warrants\ndescribed above were offered in a private placement under Section 4(a)(2) of\nthe Securities Act of 1933, as amended (the \"Act\"), and Regulation D\npromulgated thereunder and, along with the ADSs underlying the warrants, have\nnot been registered under the Act, or applicable state securities laws.\nAccordingly, the unregistered ADSs, the warrants and underlying ADSs may not\nbe offered or sold in the United States except pursuant to an effective\nregistration statement or an applicable exemption from the registration\nrequirements of the Act and such applicable state securities laws.\n\nWarrant Amendment\n\nIn connection with the offering, on August 27, 2026, the Company entered into\na warrant amendment (the \"Warrant Amendment\") pursuant to which the Company\nagreed to amend certain outstanding ordinary warrants to purchase 277,273 ADSs\npreviously issued and held by the investor in the offering. Effective as of\nthe closing of the Offering, the amended warrants (the \"Amended Warrants\")\nwill have (i) a reduced exercise price of $2.78 per ADS, and (ii) an extended\nexpiration date until August 31, 2031.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or jurisdiction\n\nAbout BioLineRx\n\nBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company\npursuing life-changing therapies in oncology and rare diseases. The Company's\n lead development asset is GLIX1, a first-in-class, oral, small molecule\ntargeting DNA damage response in glioblastoma and other solid tumors, for\nwhich a Phase 1/2a clinical trial was initiated in the first quarter of 2026.\nGLIX1 is being developed under a collaboration with Hemispherian AS.\n\nThe Company's first approved product, APHEXDA® (motixafortide), is indicated\nin the U.S. for stem cell mobilization for autologous transplantation in\nmultiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except\nAsia) and by Gloria Biosciences (in Asia). BioLineRx has retained the rights\nto develop motixafortide in metastatic pancreatic cancer (PDAC) and has a\nPhase 2b PDAC trial currently ongoing under a collaboration with Columbia\nUniversity.\n\nLearn more about who we are, what we do, and how we do it\nat www.biolinerx.com (http://www.biolinerx.com) , or on LinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements (BioLineRx)\n\nVarious statements in this release concerning BioLineRx's future expectations\nconstitute \"forward-looking statements\" within the meaning of the Private\nSecurities Litigation Reform Act of 1995. These statements include words such\nas \"anticipates,\" \"believes,\" \"could,\" \"estimates,\" \"expects,\" \"intends,\"\n\"may,\" \"plans,\" \"potential,\" \"predicts,\" \"projects,\" \"should,\" \"will,\" and\n\"would,\" and describe opinions about future events. These include statements\nregarding management's expectations, beliefs and intentions regarding, among\nother things, the completion of the offering, the satisfaction of customary\nclosing conditions related to the offering and the intended use of net\nproceeds from the offering. These forward-looking statements involve known and\nunknown risks, uncertainties and other factors that may cause the actual\nresults, performance or achievements of BioLineRx to be materially different\nfrom any future results, performance or achievements expressed or implied by\nsuch forward-looking statements. For example, BioLineRx is using\nforward-looking statements when it discusses the intended use of proceeds and\nthe expected date of closing. Factors that could cause BioLineRx's actual\nresults to differ materially from those expressed or implied in such\nforward-looking statements include, but are not limited to: the clinical\ndevelopment, commercialization and market acceptance of GLIX1 and\nmotixafortide including the degree and pace of market uptake of APHEXDA for\nthe mobilization of hematopoietic stem cells for autologous transplantation in\nmultiple myeloma patients; the initiation, timing, progress and results of\nBioLineRx's preclinical studies, clinical trials and other therapeutic\ncandidate development efforts; BioLineRx's ability to advance GLIX1 and\nmotixafortide into clinical trials or to successfully complete its preclinical\nstudies or clinical trials; whether the clinical trial results for GLIX1 and\nmotixafortide will be predictive of real-world results; BioLineRx's receipt of\nregulatory approvals for GLIX1 and motixafortide and the timing of other\nregulatory filings and approvals; whether access to GLIX1 and motixafortide is\nachieved in a commercially viable manner and whether GLIX1 and motixafortide\nreceives adequate reimbursement from third-party payors; BioLineRx's ability\nto establish, manage, and maintain corporate collaborations, as well as the\nability of BioLineRx's collaborators to execute on their development and\ncommercialization plans; BioLineRx's ability to integrate new therapeutic\ncandidates and new personnel, as well as new collaborations; the\ninterpretation of the properties and characteristics of BioLineRx's\ntherapeutic candidates and of the results obtained with its therapeutic\ncandidates in preclinical studies or clinical trials; the implementation of\nBioLineRx's business model and strategic plans for its business and\ntherapeutic candidates; the scope of protection that BioLineRx is able to\nestablish and maintain for intellectual property rights covering its\ntherapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; estimates of\nBioLineRx's expenses, future revenues, capital requirements and its need for\nand ability to access sufficient additional financing; risks related to\nchanges in healthcare laws, rules and regulations in the United States or\nelsewhere; competitive companies, technologies and BioLineRx's industry;\nBioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements\nas to the impact of the political and security situation in Israel on\nBioLineRx's business which may exacerbate the magnitude of the factors\ndiscussed above. These and other factors are more fully discussed in the \"Risk\nFactors\" section of BioLineRx's most recent annual report on Form 20-F filed\nwith the Securities and Exchange Commission on March 27, 2026. In addition,\nany forward-looking statements represent BioLineRx's views only as of the date\nof this release and should not be relied upon as representing its views as of\nany subsequent date. BioLineRx does not assume any obligation to update any\nforward-looking statements unless required by law.\n\nContacts:\n\nFor BioLineRx:\nUnited States\nChuck Padala\nLifeSci Advisors, LLC\nIR@biolinerx.com (mailto:IR@biolinerx.com)\n\nIsrael\nMoran Meir\nLifeSci Advisors, LLC\nmoran@lifesciadvisors.com (mailto:moran@lifesciadvisors.com)\n\nLogo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg\n(https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html\n(https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html)\n\nSOURCE BioLineRx Ltd.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnc49Q6Ra","title":"BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement","author":"PR Newswire","ticker":"BLRX","created":"2026-08-28T12:00:01.067Z","tickers":["BLRX"],"exchange":"NASDAQ","article_body":"BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement\n\nPR Newswire\n\nTEL AVIV, Israel, Aug. 28, 2026\n\nTEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)\n(TASE: BLRX) (\"BioLineRx\" or the \"Company\"), a clinical-stage\nbiopharmaceutical company pursuing life-changing therapies in oncology and\nrare diseases, today announced that it has entered into a definitive agreement\nfor the purchase of an aggregate of 1,348,921 of the Company's American\nDepositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per\nADS (or per ADS equivalent) through a registered direct offering. In addition,\nthe Company has agreed to issue accompanying warrants to purchase up to an\naggregate of 2,023,382 ADSs, at a purchase price of $2.78 per ADS (or per ADS\nequivalent) via a concurrent private placement. The warrants will have an\nexercise price of $2.78 per ADS and will expire five years from the issuance\ndate. Each ADS represents six hundred (600) ordinary shares, par value NIS\n0.10 per share, of BioLineRx. The closing of the offering is expected to occur\non or about August 31, 2026, subject to the satisfaction of customary closing\nconditions.\n\nChardan is acting as the exclusive placement agent for the offering.\n\nThe aggregate gross proceeds to the Company from the offering are expected to\nbe $3.75 million, before deducting the placement agent fees and other offering\nexpenses payable by the Company. The Company currently intends to use the net\nproceeds from the offering for research and development activities and working\ncapital and general corporate purposes.\n\nThe ADSs (or ADS equivalents) offered in the registered direct offering (but\nexcluding the securities offered in the private placement and the ADSs\nunderlying the warrants) are being offered pursuant to a \"shelf\" registration\nstatement (File No. 333-276323) filed with the Securities and Exchange\nCommission (\"SEC\") on December 29, 2023 and declared effective on January 5,\n2024. The offering of the ADSs (or ADS equivalents) to be issued in the\nregistered direct offering is being made only by means of a prospectus,\nincluding a prospectus supplement, forming a part of the effective\nregistration statement. A final prospectus supplement and the accompanying\nprospectus relating to the registered direct offering will be filed with the\nSEC and be available at the SEC's website at www.sec.gov (http://www.sec.gov)\n. Electronic copies of the final prospectus supplement and the accompanying\nprospectus relating to the securities being offered may also be obtained, when\navailable, by contacting Chardan at One Pennsylvania Plaza, Suite 4800, New\nYork, NY 10119, by telephone at (646) 465-9065 or e-mail at\nvdealwis@chardan.com (mailto:vdealwis@chardan.com) .\n\nThe securities issued in the private placement and the unregistered warrants\ndescribed above were offered in a private placement under Section 4(a)(2) of\nthe Securities Act of 1933, as amended (the \"Act\"), and Regulation D\npromulgated thereunder and, along with the ADSs underlying the warrants, have\nnot been registered under the Act, or applicable state securities laws.\nAccordingly, the unregistered ADSs, the warrants and underlying ADSs may not\nbe offered or sold in the United States except pursuant to an effective\nregistration statement or an applicable exemption from the registration\nrequirements of the Act and such applicable state securities laws.\n\nWarrant Amendment\n\nIn connection with the offering, on August 27, 2026, the Company entered into\na warrant amendment (the \"Warrant Amendment\") pursuant to which the Company\nagreed to amend certain outstanding ordinary warrants to purchase 277,273 ADSs\npreviously issued and held by the investor in the offering. Effective as of\nthe closing of the Offering, the amended warrants (the \"Amended Warrants\")\nwill have (i) a reduced exercise price of $2.78 per ADS, and (ii) an extended\nexpiration date until August 31, 2031.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or jurisdiction\n\nAbout BioLineRx\n\nBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company\npursuing life-changing therapies in oncology and rare diseases. The Company's\n lead development asset is GLIX1, a first-in-class, oral, small molecule\ntargeting DNA damage response in glioblastoma and other solid tumors, for\nwhich a Phase 1/2a clinical trial was initiated in the first quarter of 2026.\nGLIX1 is being developed under a collaboration with Hemispherian AS.\n\nThe Company's first approved product, APHEXDA® (motixafortide), is indicated\nin the U.S. for stem cell mobilization for autologous transplantation in\nmultiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except\nAsia) and by Gloria Biosciences (in Asia). BioLineRx has retained the rights\nto develop motixafortide in metastatic pancreatic cancer (PDAC) and has a\nPhase 2b PDAC trial currently ongoing under a collaboration with Columbia\nUniversity.\n\nLearn more about who we are, what we do, and how we do it\nat www.biolinerx.com (http://www.biolinerx.com) , or on LinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements (BioLineRx)\n\nVarious statements in this release concerning BioLineRx's future expectations\nconstitute \"forward-looking statements\" within the meaning of the Private\nSecurities Litigation Reform Act of 1995. These statements include words such\nas \"anticipates,\" \"believes,\" \"could,\" \"estimates,\" \"expects,\" \"intends,\"\n\"may,\" \"plans,\" \"potential,\" \"predicts,\" \"projects,\" \"should,\" \"will,\" and\n\"would,\" and describe opinions about future events. These include statements\nregarding management's expectations, beliefs and intentions regarding, among\nother things, the completion of the offering, the satisfaction of customary\nclosing conditions related to the offering and the intended use of net\nproceeds from the offering. These forward-looking statements involve known and\nunknown risks, uncertainties and other factors that may cause the actual\nresults, performance or achievements of BioLineRx to be materially different\nfrom any future results, performance or achievements expressed or implied by\nsuch forward-looking statements. For example, BioLineRx is using\nforward-looking statements when it discusses the intended use of proceeds and\nthe expected date of closing. Factors that could cause BioLineRx's actual\nresults to differ materially from those expressed or implied in such\nforward-looking statements include, but are not limited to: the clinical\ndevelopment, commercialization and market acceptance of GLIX1 and\nmotixafortide including the degree and pace of market uptake of APHEXDA for\nthe mobilization of hematopoietic stem cells for autologous transplantation in\nmultiple myeloma patients; the initiation, timing, progress and results of\nBioLineRx's preclinical studies, clinical trials and other therapeutic\ncandidate development efforts; BioLineRx's ability to advance GLIX1 and\nmotixafortide into clinical trials or to successfully complete its preclinical\nstudies or clinical trials; whether the clinical trial results for GLIX1 and\nmotixafortide will be predictive of real-world results; BioLineRx's receipt of\nregulatory approvals for GLIX1 and motixafortide and the timing of other\nregulatory filings and approvals; whether access to GLIX1 and motixafortide is\nachieved in a commercially viable manner and whether GLIX1 and motixafortide\nreceives adequate reimbursement from third-party payors; BioLineRx's ability\nto establish, manage, and maintain corporate collaborations, as well as the\nability of BioLineRx's collaborators to execute on their development and\ncommercialization plans; BioLineRx's ability to integrate new therapeutic\ncandidates and new personnel, as well as new collaborations; the\ninterpretation of the properties and characteristics of BioLineRx's\ntherapeutic candidates and of the results obtained with its therapeutic\ncandidates in preclinical studies or clinical trials; the implementation of\nBioLineRx's business model and strategic plans for its business and\ntherapeutic candidates; the scope of protection that BioLineRx is able to\nestablish and maintain for intellectual property rights covering its\ntherapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; estimates of\nBioLineRx's expenses, future revenues, capital requirements and its need for\nand ability to access sufficient additional financing; risks related to\nchanges in healthcare laws, rules and regulations in the United States or\nelsewhere; competitive companies, technologies and BioLineRx's industry;\nBioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements\nas to the impact of the political and security situation in Israel on\nBioLineRx's business which may exacerbate the magnitude of the factors\ndiscussed above. These and other factors are more fully discussed in the \"Risk\nFactors\" section of BioLineRx's most recent annual report on Form 20-F filed\nwith the Securities and Exchange Commission on March 27, 2026. In addition,\nany forward-looking statements represent BioLineRx's views only as of the date\nof this release and should not be relied upon as representing its views as of\nany subsequent date. BioLineRx does not assume any obligation to update any\nforward-looking statements unless required by law.\n\nContacts:\n\nFor BioLineRx:\nUnited States\nChuck Padala\nLifeSci Advisors, LLC\nIR@biolinerx.com (mailto:IR@biolinerx.com)\n\nIsrael\nMoran Meir\nLifeSci Advisors, LLC\nmoran@lifesciadvisors.com (mailto:moran@lifesciadvisors.com)\n\nLogo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg\n(https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html\n(https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html)\n\nSOURCE BioLineRx Ltd.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-28T12:00:01.105288666Z","server_sent_at_ms":1787918401105},"received_at":"2026-08-28T12:00:01.164Z","source_url":"https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html"},"analysis":{"id":"119206","press_release_id":"130298","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"BioLineRx priced a $3.75 million registered direct offering and concurrent private placement, selling approximately 1.35 million ADSs at $2.78 per share.\n\nThe transaction includes warrants to purchase up to 2.02 million ADSs and an amendment to existing warrants covering 277,273 ADSs, which lowers the exercise price to $2.78 and extends the expiration date to August 31, 2031.\n\nNet proceeds are intended for research and development activities, working capital, and general corporate purposes; Chardan acted as the exclusive placement agent.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"BioLineRx secures $3.75M in gross proceeds via direct offering and private placement with warrant sweeteners."},"keyFigures":{"dealValueUsd":3750000,"offeringPrice":2.78,"sharesOffered":1348921,"customDimensions":{"warrants_offered":2023382,"warrant_amended_shares":277273,"warrant_exercise_price":2.78,"warrant_amended_expiration":"August 31, 2031"}},"quotedText":"","namedEntities":{"people":[],"products":["GLIX1","APHEXDA","motixafortide"],"companies":[{"name":"BioLineRx Ltd.","ticker":"BLRX"},{"name":"Chardan","relationship":"placement agent"},{"name":"Hemispherian AS","relationship":"partner"},{"name":"Ayrmid Ltd.","relationship":"partner"},{"name":"Gloria Biosciences","relationship":"partner"},{"name":"Columbia University","relationship":"partner"}],"dollarAmounts":[{"amount":"$3.75 million","context":"aggregate gross proceeds from the offering"},{"amount":"$2.78","context":"purchase price per ADS"}]},"materialImpact":{"score":3,"reasoning":"The company is raising a modest $3.75 million through a registered direct offering and private placement. While not a massive dilution event, the financing includes warrants and the amendment of existing warrants to lower the exercise price and extend the term, indicating a negotiation to secure necessary capital."},"tickerRelevance":{"others":[],"primary":"BLRX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small_financing"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"BioLineRx priced a $3.75 million registered direct offering and concurrent private placement, selling approximately 1.35 million ADSs at $2.78 per share.\n\nThe transaction includes warrants to purchase up to 2.02 million ADSs and an amendment to existing warrants covering 277,273 ADSs, which lowers the exercise price to $2.78 and extends the expiration date to August 31, 2031.\n\nNet proceeds are intended for research and development activities, working capital, and general corporate purposes; Chardan acted as the exclusive placement agent.","key_figures":{"dealValueUsd":3750000,"offeringPrice":2.78,"sharesOffered":1348921,"customDimensions":{"warrants_offered":2023382,"warrant_amended_shares":277273,"warrant_exercise_price":2.78,"warrant_amended_expiration":"August 31, 2031"}},"named_entities":{"people":[],"products":["GLIX1","APHEXDA","motixafortide"],"companies":[{"name":"BioLineRx Ltd.","ticker":"BLRX"},{"name":"Chardan","relationship":"placement agent"},{"name":"Hemispherian AS","relationship":"partner"},{"name":"Ayrmid Ltd.","relationship":"partner"},{"name":"Gloria Biosciences","relationship":"partner"},{"name":"Columbia University","relationship":"partner"}],"dollarAmounts":[{"amount":"$3.75 million","context":"aggregate gross proceeds from the offering"},{"amount":"$2.78","context":"purchase price per ADS"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-28T12:04:52.127Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small_financing"}},"durationMs":83196,"modelName":"glm-4.7"}}